Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin's Marketing Authorization Application for AMR101 to Treat Huntington's Disease Accepted for review by EMEA
DUBLIN, Ireland, April 8, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that the European Medicines Agency (EMEA) has accepted for review the Company's Marketing Authorization Application (MAA) for AMR101 (ultra-pure ethyl- EPA) in patients with Huntington’s disease.
View HTML
Toggle Summary Amarin To Present At The Cowen & Company 29th Annual Health Care Conference
DUBLIN, Ireland, March 11, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Mr. Thomas Lynch, Chairman and Chief Executive Officer, will present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 8.00 am Eastern Time.
View HTML
Toggle Summary Amarin To Present At The 11th Annual BIO CEO & Investor Conference
DUBLIN, Ireland, February 3, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Mr. Thomas Lynch, Chairman and Chief Executive Officer, will present at the upcoming 11 th Annual BIO CEO & Investor Conference on Monday, February 9, 2009 at 2.45 pm Eastern Time. The event will be held
View HTML

Amarin Corporation